KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.

Francesca Sarno, Jair Tenorio, Sofia Perea, Laura Medina, Roberto Pazo-Cid, Ignacio Juez, Rocío Garcia-Carbonero, Jaime Feliu, Carmen Guillen-Ponce, Pedro P Lopez-Casas, Carmen Guerra, Yolanda Duran, José Francisco López-Acosta, Carolina Alonso, Estrella Esquivel, Ana Dopazo, Dipikaa Akshinthala, Senthil K Muthuswamy, Pablo Lapunzina, Bruno Bockorny, Manuel Hidalgo

Clin Cancer Res 31(2) 278-287

PMID39540844
PMCIDPMC11739777
DOI10.1158/1078-0432.CCR-23-4026
发表日期2024-11-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against that of the conventional treatment in PDAC. PATIENTS AND METHODS: We report a phase III trial of advanced PDAC in which patients were randomized (1:2) to a conventional treatment treated at physician's discretion (arm A) or to precision medicine (arm B). Subjects randomized to arm B underwent a tumor biopsy for whole-exome sequencing and to generate avatar mouse models and patient-derived organoids for phenotypic drug screening, with final treatment recommended by the molecular tumor board. The primary objective was median overall survival (OS). RESULTS: A total of 137 patients were enrolled with 125 randomized, 44 to arm A and 81 to arm B. Whole-exome sequencing was performed in 80.3% (65/81) patients of arm B, with potentially actionable mutations detected in 21.5% (14/65). Experimental models were generated in 16/81 patients (19.8%). Second-line treatment was administered to 39 patients in the experimental arm, but only four (10.2%) received personalized treatment, whereas 35 could not receive matched therapy because of rapid clinical deterioration, delays in obtaining study results, or the absence of actionable targets. The median OS was 8.7 and 8.6 months (P = 0.849) and the median progression-free survival was 3.8 and 4.3 months (P = 0.563) for the conventional and experimental arms, respectively. Notably, the four patients who received personalized treatment had a median OS of 19.3 months. CONCLUSIONS: Personalized medicine was challenging to implement in most patients with PDAC, limiting the interpretation of intention-to-treat analysis. Survival was improved in the subset of patients who did receive matched therapy.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 4.

OS. Kaplan–Meier estimate of OS in the ITT population (arm A, n = 44; arm B, n = 81). Survival measured in months from the time of randomization. + and × displayed in the curves identify censoring pattern.

OS

OS

Figure 4. · Panel OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study design. PD, progressive disease.
非 KM Figure
Figure 2.CONSORT diagram. Subjects in whom personalized treatment was not administered ( n = 35) may have more than one overlapping reason.
非 KM Figure
Figure 3.Summary of WES data. Columns represent each study sample analyzed for WES ( n = 76). Rows represent genes in which relevant variants were detected with their respective prevalence. Genetic variants were classified as somatic and germline, as detailed in the color-coded legend. In 26 samples, no mosaic or neither germline variants were identified.
非 KM Figure